Cysteine-rich Intestinal Protein 1 Suppresses Apoptosis and Chemosensitivity to 5-fluorouracil in Colorectal Cancer Through Ubiquitin-mediated Fas Degradation

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2019 Mar 10

PMID 30850009

Citations 20

Authors

Lanzhi Zhang

Rui Zhou

Weibin Zhang

Xueqing Yao

Weidong Li

Lijun Xu

Xuegang Sun

Liang Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Cysteine-rich intestinal protein 1 (CRIP1) is highly expressed in human intestine and aberrantly expressed in several types of tumor. However, studies on CRIP1 are limited and its role on tumor development and progression remains controversial and elusive.

Methods: Immunohistochemistry was performed to evaluate the expression of CRIP1 in paired normal and colorectal tumor specimens, as well as colorectal cell lines. Functional assays, such as CCK8, TUNEL assay and in vivo tumor growth assay, were used to detect the proliferation, apoptosis and response to 5-FU of CRIP1. Western blot was used to analyze Fas-mediated pathway induced by CRIP1. Rescue experiments were performed to evaluate the essential role of CRIP1 for Fas-mediated apoptosis.

Results: We demonstrated that CRIP1 is overexpressed in CRC tissues compared with adjacent normal mucosa. CRIP1 could dramatically recover the 5-Fluorouracil (5-FU) inhibited CRC cell proliferation in vitro and stimulate the tumor formation of CRC in vivo, probably through inhibiting CRC cell apoptosis. Moreover, CRIP1 also dramatically recovered the 5-Fluorouracil (5-FU) induced tumor cell apoptosis in vitro. Further study demonstrated that CRIP1 down-regulated the expression of Fas protein and proteins related to Fas-mediated apoptosis. CRIP1 could interact with Fas protein and stimulate its ubiquitination and degradation. In addition, a negative correlation was detected between the expression of CRIP1 and Fas protein in most of the clinical human CRC samples.

Conclusion: The current research reveals a vital role of CRIP1 in CRC progression, which provide a novel target for clinical drug resistance of colorectal cancer and undoubtedly contributing to the therapeutic strategies in CRC.

Citing Articles

Single-cell transcriptomic and T cell antigen receptor analysis of human cytomegalovirus (hCMV)-specific memory T cells reveals effectors and pre-effectors of CD8- and CD4-cytotoxic T cells.

Kar R, Chattopadhyay S, Sharma A, Sharma K, Sinha S, Arimbasseri G Immunology. 2024; 172(3):420-439.

PMID: 38501302 PMC: 7616077. DOI: 10.1111/imm.13783.

CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy.

Tang P, Yu Z, Sun H, Liu L, Gong L, Fang T EBioMedicine. 2024; 100:104961.

PMID: 38199044 PMC: 10825369. DOI: 10.1016/j.ebiom.2023.104961.

Major vault protein (MVP) suppresses aging- and estrogen deficiency-related bone loss through Fas-mediated apoptosis in osteoclasts.

Wang R, Yang Y, Zhang Z, Zhao N, Wiemer E, Ben J Cell Death Dis. 2023; 14(9):604.

PMID: 37704623 PMC: 10500014. DOI: 10.1038/s41419-023-05928-4.

Unraveling the activation process and core driver genes of HSCs during cirrhosis by single-cell transcriptome.

Li X, Wang Q, Ai L, Cheng K Exp Biol Med (Maywood). 2023; 248(16):1414-1424.

PMID: 37674431 PMC: 10657590. DOI: 10.1177/15353702231191109.

CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma.

Liu X, Tang R, Xu J, Tan Z, Liang C, Meng Q Gut. 2023; 72(12):2329-2343.

PMID: 37541772 PMC: 10715495. DOI: 10.1136/gutjnl-2022-329349.

References

Cousins R, Lanningham-Foster L . Regulation of cysteine-rich intestinal protein, a zinc finger protein, by mediators of the immune response. J Infect Dis. 2000; 182 Suppl 1:S81-4. DOI: 10.1086/315917. View

Saltz L, Cox J, Blanke C, Rosen L, Fehrenbacher L, Moore M . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343(13):905-14. DOI: 10.1056/NEJM200009283431302. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P . Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol. 2002; 160(5):1745-54. PMC: 1850868. DOI: 10.1016/S0002-9440(10)61121-2. View

Lanningham-Foster L, Green C, Langkamp-Henken B, Davis B, Nguyen K, Bender B . Overexpression of CRIP in transgenic mice alters cytokine patterns and the immune response. Am J Physiol Endocrinol Metab. 2002; 282(6):E1197-203. DOI: 10.1152/ajpendo.00508.2001. View

Chen Y, Miller C, Mosher R, Zhao X, Deeds J, Morrissey M . Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res. 2003; 63(8):1927-35. View

Johannessen M, Moller S, Hansen T, Moens U, Van Ghelue M . The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci. 2006; 63(3):268-84. PMC: 11136317. DOI: 10.1007/s00018-005-5438-z. View

Smid M, Wang Y, Klijn J, Sieuwerts A, Zhang Y, Atkins D . Genes associated with breast cancer metastatic to bone. J Clin Oncol. 2006; 24(15):2261-7. DOI: 10.1200/JCO.2005.03.8802. View

Groene J, Mansmann U, Meister R, Staub E, Roepcke S, Heinze M . Transcriptional census of 36 microdissected colorectal cancers yields a gene signature to distinguish UICC II and III. Int J Cancer. 2006; 119(8):1829-36. DOI: 10.1002/ijc.22027. View

10.

Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J . Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene. 2007; 26(45):6560-5. DOI: 10.1038/sj.onc.1210472. View

11.

Butler B, Kastendieck D, Cooper J . Differently phosphorylated forms of the cortactin homolog HS1 mediate distinct functions in natural killer cells. Nat Immunol. 2008; 9(8):887-97. PMC: 2622733. DOI: 10.1038/ni.1630. View

12.

Klein A, Olendrowitz C, Schmutzler R, Hampl J, Schlag P, Maass N . Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett. 2008; 276(2):212-20. DOI: 10.1016/j.canlet.2008.11.017. View

13.

Hempe J, Cousins R . Cysteine-rich intestinal protein binds zinc during transmucosal zinc transport. Proc Natl Acad Sci U S A. 1991; 88(21):9671-4. PMC: 52780. DOI: 10.1073/pnas.88.21.9671. View

14.

Freyd G, Kim S, Horvitz H . Novel cysteine-rich motif and homeodomain in the product of the Caenorhabditis elegans cell lineage gene lin-11. Nature. 1990; 344(6269):876-9. DOI: 10.1038/344876a0. View

15.

Center M, Jemal A, Smith R, Ward E . Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009; 59(6):366-78. DOI: 10.3322/caac.20038. View

16.

Zhao L, Wang H, Liu C, Liu Y, Wang X, Wang S . Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1. Gut. 2010; 59(9):1226-35. DOI: 10.1136/gut.2009.202739. View

17.

Sharma A, Narain N, Handel E, Iken M, Singhal N, Cathomen T . MicroRNA-221 regulates FAS-induced fulminant liver failure. Hepatology. 2011; 53(5):1651-61. DOI: 10.1002/hep.24243. View

18.

Balluff B, Rauser S, Meding S, Elsner M, Schone C, Feuchtinger A . MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol. 2011; 179(6):2720-9. PMC: 3260837. DOI: 10.1016/j.ajpath.2011.08.032. View

19.

Baumhoer D, Elsner M, Smida J, Zillmer S, Rauser S, Schoene C . CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients. Oncotarget. 2011; 2(12):970-5. PMC: 3282102. DOI: 10.18632/oncotarget.398. View

20.

Jeschke J, Van Neste L, Glockner S, Dhir M, Calmon M, Deregowski V . Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics. 2012; 7(7):701-9. DOI: 10.4161/epi.20445. View